Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.

Jisoo A. Kwon | R. Malekzadeh | F. Tacke | Chien-Jen Chen | V. de Lédinghen | M. Buti | J. Lazarus | H. Poustchi | B. Cowie | B. Uzochukwu | F. Sanai | T. Asselah | C. Yurdaydın | C. Stedman | X. Forns | J. Kao | M. Yuen | W. Seto | M. Hellard | A. Hatzakis | H. Razavi | L. Ferradini | Z. Abbas | S. Hamid | V. Saraswat | S. Tan | R. Mohamed | G. Dore | J. Shim | K. Kaita | C. Coffin | R. Stauber | D. Lavanchy | C. Sarrazin | W. Laleman | P. Lampertico | S. Merat | V. T. Nguyen | D. Sinn | R. D. de Knegt | D. Roulot | U. Akarca | M. Brunetto | I. Waked | J. Crespo | I. Tolmane | P. Lázaro | B. Müllhaupt | G. Choudhuri | S. Ahn | Ming‐Lung Yu | E. Gane | N. Janjua | J. Grebely | Cheng‐Hung Chien | Ching‐Chih Hu | R. Flisiak | E. Zuckerman | A. Johannessen | R. Njouom | K. Athanasakis | O. Opare-Sem | Yao-Chun Hsu | A. Vince | Christophe Moreno | A. Craxì | J. Cabezas | R. Safadi | G. Wong | Kaarlo Simojoki | P. Ocama | F. Cui | N. Örmeci | A. Aghemo | V. Sypsa | C. Osiowy | A. Khan | F. Bessone | F. Khamis | D. Shouval | M. Gschwantler | J. Jaroszewicz | P. Bruggmann | B. Hajarizadeh | M. El-Sayed | M. Sonneveld | H. Chan | G. Papatheodoridis | W. Chuang | H. Qureshi | N. Prabdial-Sing | A. Sharara | G. Muyldermans | V. Liakina | M. Janíčko | P. Jarčuška | A. Nersesov | I. Hasan | M. Biondi | W. Sievert | S. Ryder | T. Tsang | S. Egeonu | C. Seguin-Devaux | A. Thompson | V. Chulanov | O. Dalgard | Z. Ben‐Ari | S. Dražilová | A. Yosry | A. Ramji | Said A. Al-Busafi | M. Mendes-Corrêa | K. Tomasiewicz | J. García-Samaniego | T. Casanovas | O. Etzion | A. Bizri | T. Pham | N. Coppola | T. Vanwolleghem | W. Al-Hamoudi | C. Estes | H. Midgard | Pouya Goleij | P. Gholam | I. Gamkrelidze | E. Ridruejo | P. Christensen | N. Weis | W. Braga | S. Aleman | C. Brandão-Mello | C. Brosgart | M. Gottfredsson | A. Harris | J. Ong | H. Cheinquer | M. Cramp | A. Alghamdi | I. Altraif | F. Alfaleh | K. Razavi-Shearer | J. Sperl | C. Pan | U. Saeed | P. Husa | B. V. van Welzen | S. Oguche | Y. Lim | T. Yip | R. Gish | R. Salupere | L. Mortgat | S. Blach | M. Kåberg | M. Naveira | M. Andersson | J. Genov | B. Lukšić | O. Kheir | Motswedi Anderson | O. Sagalova | A. Aljumah | W. Hamoudi | Peyton Thompson | I. Aho | Q. Ning | K. Al-Naamani | M. Sonderup | C. Spearman | L. Kondili | Richard Phillips | P. Kristian | O. Baatarkhuu | L. Cisneros | N. Pimenov | I. Schreter | N. Sargsyants | M. Lagging | M. Peck‐Radosavljevic | J. Amarsanaa | Ivana Hockicková | D. Jelev | James Fung | C. Yaghi | J. Mokhbat | K. Yesmembetov | N. Guingané | L. Gheorghe | Paige A. Armstrong | Shakhlo Sadirova | Manik Gemilyan | A. Malu | John Rwegasha | M. Orrego | Manuel Rodríguez | E. Musabaev | K. Kaliaskarova | I. Khoudri | A. Konysbekova | C. Omuemu | A. Jēruma | P. Ferreira | V. Wong | R. Ntagirabiri | Gulya Sarybayeva | A. Bensalem | A. Al-Rifai | J. Hercun | H. Rautiainen | Chris Cunningham | Abduljaleel M. Alalwan | Stuart Roberts | C. Chae | J. Hernández | B. Meshesha | Nasser Al Masri | T. Tergast | Cora Pop | Cong Wang | Pei‐Jer Chen | Norah Terrault | Mahdi Sheikh | Jidong Jia | R. Gray | M. Elbadri | E. Farag | M. El‐Kassas | Fernando Contreras | Mei‐Hsuan Lee | Jaw‐Ching Wu | A. Kelly‐Hanku | M. Anderson | Ken Cheng | Myeong-Eun Cheon | S. Zeuzem | M. Pessoa | S. Ribeiro | Sanaa Said | Ellen Mooneyhan | J. Kwon | Virginia Garcia | María E Robalino | S. Fraňková | J. Sánchez-Ávila | Alice U Lee | C. Ríos-Hincapié | T. Tergast | A. Voeller | R. Marinho | H. Mekonnen | R. Brown Jr | F. Negro | Ayat Abdallah | Lewis Roberts | S. Alavian | Junko Tanaka | M. Simonova | D. Razavi‐Shearer | M. Cornberg | Mia J. Biondi | J. Wallace | T. Berg | Yasir Waheed | D. Plaseska‐Karanfilska | Ann-Sofi Duberg | S. Ahmadbekova | Yousif Alserkal | K. Brown | Diana Librado | Z. Nurmatov | Loreley Pincay-Rodríguez | Samir Shah | Remak William | I. Schréter | Robert R. Gish | G. Wong | Ming‐Lung Yu | Jae-Jun Shim | Zuridin S Nurmatov | A. Alalwan | M. Robalino | Khalid Al-Naamani

[1]  A. de Gottardi,et al.  The current and future burden of hepatitis B in Switzerland: a modelling study. , 2023, Swiss medical weekly.

[2]  H. Razavi,et al.  The impact of immigration on hepatitis B burden in the United States: a modelling study , 2023, Lancet regional health. Americas.

[3]  T. Hallett,et al.  Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study. , 2023, The lancet. Gastroenterology & hepatology.

[4]  J. Parr,et al.  Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries. , 2023, The Journal of infectious diseases.

[5]  [Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]. , 2022, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[6]  An open letter to Gavi: hepatitis B birth dose vaccine can't wait , 2022, The Lancet Gastroenterology & Hepatology.

[7]  N. Khetsuriani,et al.  Progress Toward the Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Worldwide, 2016–2021 , 2022, MMWR. Morbidity and mortality weekly report.

[8]  C. Sanmartin,et al.  Hospitalization related to chronic hepatitis B and C in recent immigrants in Canada: An immigration administrative data-linked, population-based cohort study. , 2022, Health reports.

[9]  Lalu Muhammad Irham,et al.  Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The lancet. Gastroenterology & hepatology.

[10]  A. Duberg,et al.  Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study , 2022, Hepatology communications.

[11]  C. de Martel,et al.  Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review , 2022, The lancet. Gastroenterology & hepatology.

[12]  M. M. Hasan,et al.  Impact of COVID‐19 pandemic on viral hepatitis in Africa: Challenges and way forward , 2021, The International journal of health planning and management.

[13]  M. Buti,et al.  A novel model of care for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain , 2021, Scientific Reports.

[14]  Elin Hoffmann Dahl,et al.  Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C , 2021, Journal of viral hepatitis.

[15]  E. Gane,et al.  Position statement on the use of Tenofovir Alafenamide for the treatment of chronic Hepatitis B Virus infection in Africa , 2021, Gastroenterology & Hepatology: Open Access.

[16]  A. Tanaka.  JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update. , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  T. Asselah,et al.  Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development. , 2020, Journal of hepatology.

[18]  V. Wong,et al.  Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. , 2020, The American journal of gastroenterology.

[19]  J. Ferlay,et al.  Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. , 2019, The Lancet. Global health.

[20]  M. Ieven,et al.  Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population , 2019, Annals of global health.

[21]  N. Hens,et al.  Prevalence and risk factors of hepatitis B virus infection in Middle‐Limburg Belgium, year 2017: Importance of migration , 2019, Journal of medical virology.

[22]  Steven R. Martin,et al.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. , 2018, Canadian liver journal.

[23]  Hwai I. Yang,et al.  Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score–Matched Study , 2018, The Journal of infectious diseases.

[24]  M. Plummer,et al.  Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide , 2018, International journal of cancer.

[25]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[26]  Y. Tse,et al.  Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[28]  T. Hallett,et al.  Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.

[29]  J. Salas-Coronas,et al.  Viral hepatitis and immigration: A challenge for the healthcare system. , 2016, Revista clinica espanola.

[30]  R. Mikolajczyk,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[31]  J. Feld,et al.  Immigration and viral hepatitis. , 2015, Journal of hepatology.

[32]  V. Hope,et al.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association , 2013, Epidemiology and Infection.

[33]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[34]  Chien-Jen Chen,et al.  Natural history of chronic hepatitis B REVEALed , 2011, Journal of gastroenterology and hepatology.

[35]  C. Chu,et al.  HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long‐term follow‐up , 2007, Hepatology.

[36]  M. Raptopoulou-Gigi,et al.  Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[37]  J. Koskinas,et al.  Natural history of chronic HBV infection: A cohort study with up to 12 years follow‐up in North Greece (part of the Interreg I‐II/EC‐project) , 2005, Journal of medical virology.

[38]  Y. N. Park,et al.  Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. , 2005, Journal of hepatology.

[39]  S. Kaneko,et al.  Clearance of HBsAg in seven patients with chronic hepatitis B , 1992, Hepatology.

[40]  D. Malcolm,et al.  Application of a Technique for Research and Development Program Evaluation , 1959 .

[41]  Ding‐Shinn Chen,et al.  Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. , 2010, Advances in cancer research.

[42]  Z. Duan,et al.  [The guidelines of prevention and treatment for chronic hepatitis B]. , 2005, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.